The primary endpoints were clinical remission for UC patients (mMS 2) and endoscopic response for CD patients (50% SES-CD reduction), with inclusion criteria requiring IBD diagnosis for 3 months, moderate to severe disease activity, and inadequate response to prior therapies, while excluding patients with active infections, malignancy, immunocompromised states, or pregnancy
This label serves as proof that the medication is legitimately prescribed to you
[01:33] B Yeah, yeah, you've been
These animal findings are often cited in community frameworks but represent animal data in aged, often GH-deficient models, not healthy adult humans
Snow, B
Life-altering, some of them, but others just a long-term irritant